The BCIRG 006 trial is relevant for all Her2 positive disease, both ER positive and ER negative. Depending on the risk profile of the patient (T2 disease and beyond), I give T...

Worth noting that ER/PR status would impact this decision -- significant residual disease in a HR+ HER2+ patient would potentially argue for moving on to endocrine therapy rat...

I would treat this patient with chemotherapy and anti Her-2 therapy. Her-2 positive disease has a higher risk of distant recurrence and as long as the primary tumor is >0.5...

I tend to reserve neo-adjuvant chemotherapy for patients with cT2 or higher if there is no clinical evidence of positive lymph nodes. The results of APT trial that enrolled pa...

This becomes a philosophical question...arguments can be made for either approach. My approach is to offer everything within reason, as opposed to omitting parts of treatment ...

High Ki-67 are common in Her 2 Positive cancers and will be expected in higher grade tumors. I don't think we have good data to escalate treatment based on those factors. I wo...

So far, insurance companies in my area are not approving TDM1 in this setting because there is no overall survival advantage at this point.

I agree that TCHP is equivalent to AC-TH with less cardiac toxicity. 

I would switch to weekly paclitaxel and carboplatin with trastuzumab only, but might retry pertuzumab if the patient gets through 6 weeks without recurrent diarrhea. This is a...